Weekly Spotlight - 10.10.24

In the News

Cilta-Cel Proves Effective and Safe for Myeloma Patients in Real-World Settings

Cilta-cel, a CAR T-cell therapy, shows promise in treating relapsed/refractory myeloma, achieving high response rates and acceptable safety in real-world settings. Despite many patients not meeting trial criteria, the therapy's efficacy and safety align with clinical data, offering hope for those with complex medical histories. High response rates in diverse patient groups. Consistent safety profile with clinical trials. Challenges include managing delayed neurotoxicity and nonrelapse mortality. Many patients had high-risk features and prior treatments. Real-world patients often differ from trial participants, highlighting the therapy's adaptability.

Understanding the Subtle NF-B Activation in Multiple Myeloma

The study explores the interaction between multiple myeloma and stromal cells, revealing mild NF-B activation in a minority of cells. This activation is influenced by the bone marrow environment and IL-1 signalling. Understanding these dynamics could enhance treatment strategies, offering hope for improved patient outcomes. Mild NF-B activation is influenced by the bone marrow environment and IL-1-dependent communication between stromal and MM cells. The findings suggest that therapies like Anakinra, an IL-1 inhibitor, could play a crucial role in managing MM by modulating the inflammatory environment.

New Hope for Multiple Myeloma Patients with Innovative Drug Combination

The study explores the combination of belantamab mafodotin and nirogacestat for treating relapsed multiple myeloma. These drugs aim to slow cancer growth. Participants must have persistent myeloma despite prior treatments. The research seeks the safest, most effective dosage, offering hope for improved patient outcomes. This Phase IB study explores the combination of belantamab mafodotin and nirogacestat for individuals with relapsed or persistent multiple myeloma. The aim is to determine the safest and most effective dose of belantamab mafodotin when used with nirogacestat. Participants must have multiple myeloma that has returned or progressed despite previous treatments.

Delayed Treatment in Myeloma Patients Linked to Race and Age Disparities

The study highlights disparities in the timely initiation of oral antimyeloma treatments, particularly affecting Black and older patients. Despite advancements in treatment, barriers remain, such as complex prescription processes. Addressing these challenges is crucial for equitable care and improved outcomes in multiple myeloma treatment. A recent study highlights disparities in the timing of oral antimyeloma treatment initiation, particularly affecting Black individuals and older adults. Despite advancements in treatment, these groups are less likely to receive timely prescriptions, with significant delays noted. Efforts are underway to identify and mitigate these challenges, aiming to ensure timely and equitable treatment for all patients.

Scottish Myeloma Patients Gain Hope with New Treatment Options

Two innovative treatments for myeloma, SVD and SD, have been approved in Scotland, offering remissions of up to 13 months. These treatments provide new options for patients resistant to existing therapies. The approval highlights a significant advancement in myeloma care, offering hope and improved outcomes for affected individuals. In Scotland, two innovative treatments, SVD and SD, have been approved, offering hope to myeloma patients. Selinexor's unique mechanism blocks a protein that myeloma cells exploit, allowing tumour suppressor proteins to accumulate and kill the cancer cells. This approval is a beacon of hope, ensuring patients have more options to manage their disease effectively.

Karen Paul's Inspiring Journey: A Beacon of Hope for Myeloma UK

Karen Paul, diagnosed with smouldering myeloma, joined Myeloma UK as a Trustee in 2022. She organised a successful Gala Dinner in 2024, raising funds and awareness. Her personal speech connected deeply with attendees, highlighting the importance of understanding myeloma. Karen's dedication exemplifies the impact of volunteering. Karen Paul, diagnosed with smouldering myeloma in 2020, has been a dedicated volunteer for Myeloma UK. Her involvement began with attending fundraising events, and in 2022, she joined the Myeloma UK Board as a Trustee. Her efforts, including securing guests, prizes, and sponsorship, made the event a success.